Lv4
403 积分 2021-04-02 加入
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC
3天前
已完结
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non–Small Cell Lung Cancer
18天前
已完结
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study
18天前
已完结
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1
18天前
已完结
[Clinical practice guideline for brain metastases of lung cancer in China (2021 version)]
18天前
已完结
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC
24天前
已完结
5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC
24天前
已完结
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
24天前
已完结
Pulmonary arterial blowout syndrome as a serious adverse event in patients with advanced lung cancer: a 12-year retrospective study
27天前
已完结
Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer
30天前
已完结
皖公网安备34019202002308
